BT has announced that Berg Pharma and BT Global Services will be working together to accelerate the process of drug discovery and development, using resources and technology from both companies. The joint effort will focus on the use of innovative approaches to target identification and validation and on lead optimization of novel drug candidates. It will support the use of cloud-based high throughput molecular profiling techniques to select patients for clinical trials.
Berg Pharma will use the BT for Life Sciences R&D cloud service as the de facto standard for running Berg's unique Interrogative Biology platform. BT for Life Sciences R&D, unveiled at the 10th Bio-IT World meeting, is the first cloud service designed to enable collaboration within the life sciences industry for increased R&D productivity.